{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:16:29Z","timestamp":1707524189707},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,30]]},"DOI":"10.7759\/cureus.10732","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T14:40:08Z","timestamp":1601476808000},"source":"Crossref","is-referenced-by-count":1,"title":["Chlorpromazine-Induced Relapse of Tourette Syndrome in a Patient With Intellectual Disability, Attention Deficit Hyperactivity Disorder, and Schizophrenia"],"prefix":"10.7759","author":[{"given":"Anum","family":"Maqsood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salman","family":"Akram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faisal","family":"Akram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.57.8.1383","article-title":"Prevalence of tics in schoolchildren and association with placement in special education","volume":"57","author":"Kurlan R","year":"2001","unstructured":"Kurlan R, McDermott MP, Deeley C, et al.. Prevalence of tics in schoolchildren and association with placement in special education. Neurology. 2001, 57:1383-1388. 10.1212\/wnl.57.8.1383","journal-title":"Neurology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(14)00132-1","article-title":"A personal 35 year perspective on Gilles de la Tourette syndrome: prevalence, phenomenology, comorbidities, and coexistent psychopathologies","volume":"2","author":"Robertson MM","year":"2015","unstructured":"Robertson MM. A personal 35 year perspective on Gilles de la Tourette syndrome: prevalence, phenomenology, comorbidities, and coexistent psychopathologies. Lancet Psychiatry. 2015, 2:68-87. 10.1016\/S2215-0366(14)00132-1","journal-title":"Lancet Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1542\/peds.102.1.14","article-title":"Course of tic severity in Tourette syndrome: the first two decades","volume":"102","author":"Leckman JF","year":"1998","unstructured":"Leckman JF, Zhang H, Vitale A, et al.. Course of tic severity in Tourette syndrome: the first two decades. Pediatrics. 1998, 102:14-19. 10.1542\/peds.102.1.14","journal-title":"Pediatrics"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-007-1003-7","article-title":"Tic disorders and ADHD: answers from a world-wide clinical dataset on Tourette syndrome","volume":"16","author":"Freeman RD","year":"2007","unstructured":"Freeman RD, Tourette Syndrome International Database Consortium. Tic disorders and ADHD: answers from a world-wide clinical dataset on Tourette syndrome. Eur Child Adolesc Psychiatry. 2007, 16:15-23. 10.1007\/s00787-007-1003-7","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0559-8","article-title":"Antipsychotic-associated symptoms of Tourette syndrome: a systematic review","volume":"32","author":"Kim DD","year":"2018","unstructured":"Kim DD, Barr AM, Chung Y, et al.. Antipsychotic-associated symptoms of Tourette syndrome: a systematic review. CNS Drugs. 2018, 32:917-38. 10.1007\/s40263-018-0559-8","journal-title":"CNS Drugs"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S79863","article-title":"Aripiprazole-associated tic in a schizophrenia patient","volume":"11","author":"Guo X","year":"2015","unstructured":"Guo X, Lu D, Jiang Y. Aripiprazole-associated tic in a schizophrenia patient. Neuropsychiatr Dis Treat. 2015, 11:873-874. 10.2147\/NDT.S79863","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/01.WNF.0000223541.57501.BB","article-title":"Amisulpride-induced tardive motor and phonic tics","volume":"29","author":"Alonso-Navarro H","year":"2006","unstructured":"Alonso-Navarro H, Jimenez-Jimenez FJ. Amisulpride-induced tardive motor and phonic tics. Clin Neuropharmacol. 2006, 29:163-164. 10.1097\/01.WNF.0000223541.57501.BB","journal-title":"Clin Neuropharmacol"},{"key":"ref8","article-title":"Exacerbation of motor tic and induction of new tic by haloperidol use","volume":"156","author":"Diaz JM","year":"1992","unstructured":"Diaz JM, Smith KG, Maccario M. Exacerbation of motor tic and induction of new tic by haloperidol use. West J Med. 1992, 156:198-199.","journal-title":"West J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.143.9.1176","article-title":"Neuroleptic-induced tics in two hyperactive children","volume":"143","author":"Gualtieri CT","year":"1986","unstructured":"Gualtieri CT, Patterson DR. Neuroleptic-induced tics in two hyperactive children. Am J Psychiatry. 1986, 143:1176-1177. 10.1176\/ajp.143.9.1176","journal-title":"Am J Psychiatry"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v63n1214i","article-title":"A case report of quetiapine-related tic-like symptoms","volume":"63","author":"Huang SC","year":"2002","unstructured":"Huang SC, Lai TJ, Tsai SJ. A case report of quetiapine-related tic-like symptoms. J Clin Psychiatry. 2002, 63:1184-1185. 10.4088\/jcp.v63n1214i","journal-title":"J Clin Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-005-0448-z","article-title":"Pergolide improvement in neuroleptic-resistant Tourette cases: various mechanisms causing tics","volume":"26","author":"Cianchetti C","year":"2005","unstructured":"Cianchetti C, Fratta A, Pisano T, Minafra L. Pergolide improvement in neuroleptic-resistant Tourette cases: various mechanisms causing tics. Neurol Sci. 2005, 26:137-139. 10.1007\/s10072-005-0448-z","journal-title":"Neurol Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870120320","article-title":"Dopamine agonist treatment of Tourette disorder in children: results of an open-label trial of pergolide","volume":"12","author":"Lipinski JF","year":"1997","unstructured":"Lipinski JF, Sallee FR, Jackson C, Sethuraman G. Dopamine agonist treatment of Tourette disorder in children: results of an open-label trial of pergolide. Mov Disord. 1997, 12:402-407. 10.1002\/mds.870120320","journal-title":"Mov Disord"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000044058.64647.7e","article-title":"Tic reduction with pergolide in a randomized controlled trial in children","volume":"60","author":"Gilbert DL","year":"2003","unstructured":"Gilbert DL, Dure L, Sethuraman G, Raab D, Lane J, Sallee FR. Tic reduction with pergolide in a randomized controlled trial in children. Neurology. 2003, 60:606-611. 10.1212\/01.wnl.0000044058.64647.7e","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.54.6.1310","article-title":"Tourette's syndrome improvement with pergolide in a randomized, double-blind, crossover trial","volume":"54","author":"Gilbert DL","year":"2000","unstructured":"Gilbert DL, Sethuraman G, Sine L, Peters S, Sallee FR. Tourette's syndrome improvement with pergolide in a randomized, double-blind, crossover trial. Neurology. 2000, 54:1310-1315. 10.1212\/wnl.54.6.1310","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.8.1329","article-title":"Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET","volume":"159","author":"Singer HS","year":"2002","unstructured":"Singer HS, Szymanski S, Giuliano J, et al.. Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. Am J Psychiatry. 2002, 159:1329-1336. 10.1176\/appi.ajp.159.8.1329","journal-title":"Am J Psychiatry"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301528","article-title":"Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET","volume":"33","author":"Wong DF","year":"2008","unstructured":"Wong DF, Brasic JR, Singer HS, et al.. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology. 2008, 33:1239-1251. 10.1038\/sj.npp.1301528","journal-title":"Neuropsychopharmacology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-018-0202-y","article-title":"Striatal dopaminergic alterations in Tourette's syndrome: a meta-analysis based on 16 PET and SPECT neuroimaging studies","volume":"8","author":"Hienert M","year":"2018","unstructured":"Hienert M, Gryglewski G, Stamenkovic M, Kasper S, Lanzenberger R. Striatal dopaminergic alterations in Tourette's syndrome: a meta-analysis based on 16 PET and SPECT neuroimaging studies. Transl Psychiatry. 2018, 8:143. 10.1038\/s41398-018-0202-y","journal-title":"Transl Psychiatry"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0502624102","article-title":"Altered parvalbumin-positive neuron distribution in basal ganglia of individuals with Tourette syndrome","volume":"102","author":"Kalanithi PS","year":"2005","unstructured":"Kalanithi PS, Zheng W, Kataoka Y, et al.. Altered parvalbumin-positive neuron distribution in basal ganglia of individuals with Tourette syndrome. Proc Natl Acad Sci USA. 2005, 102:13307-13312. 10.1073\/pnas.0502624102","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/cne.22206","article-title":"Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndrome","volume":"518","author":"Kataoka Y","year":"2010","unstructured":"Kataoka Y, Kalanithi PS, Grantz H, Schwartz ML, Saper C, Leckman JF, Vaccarino FM. Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndrome. J Comp Neurol. 2010, 518:277-291. 10.1002\/cne.22206","journal-title":"J Comp Neurol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2018.02.004","article-title":"Future directions in tardive dyskinesia research","volume":"389","author":"Meyer JM","year":"2018","unstructured":"Meyer JM. Future directions in tardive dyskinesia research. J Neurol Sci. 2018, 389:76-80. 10.1016\/j.jns.2018.02.004","journal-title":"J Neurol Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/40723-chlorpromazine-induced-relapse-of-tourette-syndrome-in-a-patient-with-intellectual-disability-attention-deficit-hyperactivity-disorder-and-schizophrenia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:23:37Z","timestamp":1707506617000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/40723-chlorpromazine-induced-relapse-of-tourette-syndrome-in-a-patient-with-intellectual-disability-attention-deficit-hyperactivity-disorder-and-schizophrenia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,30]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.10732","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,30]]}}}